At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 63 enrolled
Drug / intervention
Bempedoic acid 180mg +3 moredrug
Likely dose
Bempedoic acid 180mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Triplet Therapy With Bempedoic Acid (ETC 1002) 180 mg, Ezetimibe 10 mg, and Atorvastatin 20 mg in Patients With Elevated LDL C
In Brief
A Phase 2 clinical trial evaluating Bempedoic acid 180mg, Ezetimibe 10mg, and 2 other interventions for Hypercholesterolemia. Completed, enrolled 63 participants across 11 sites.
Detailed Summary
The purpose of this study is to determine if triplet therapy with bempedoic acid (ETC-1002) 180mg, ezetimibe 10mg, and atorvastatin 20mg is effective and safe versus placebo in patients with elevated LDL cholesterol.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypercholesterolemia
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartJan 2017
First PostedFeb 2017
Primary CompletionJun 2017
Study CompletionJul 2017
TodayJul 2026
First PostedFeb 13, 2017
Enrollment StartJan 19, 2017
Primary CompletionJun 1, 2017
Study CompletionJul 5, 2017
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 9.4 years ago
Interventions
Bempedoic acid 180mgdrug
bempedoic acid 180 mg
Ezetimibe 10mgdrug
ezetimibe 10 mg
Atorvastatin 20mgdrug
atorvastatin 20 mg
Placeboother
placebo